The use of GDF-15, soluble ST2, and galectin-3 as diagnostic tools presents a promising strategy for the early detection of diseases, categorizing risk, and enhancing patient outcomes in various medical conditions, including cardiovascular diseases. This evidence concerns the gene LGALS3 and cardiovascular disorder.